NCT04885218View on ClinicalTrials.gov

Efficacy and Safety of SHR-1209 Combined With Lipid-lowering Agents in Patients With Hypercholesterolemia

PHASE3CompletedINTERVENTIONAL
Enrollment

692

Participants

Timeline

Start Date

July 30, 2021

Primary Completion Date

May 23, 2023

Study Completion Date

May 23, 2023

Conditions
Non-familial HypercholesterolemiaMixed Hyperlipidemia
Interventions
DRUG

SHR-1209 ;placebo

SHR-1209 and placebo 150 mg subcutaneous injection once every 4 weeks for 48 weeks

DRUG

SHR-1209 ;placebo

SHR-1209 and placebo 300 mg subcutaneous injection once every 8 weeks for 48 weeks

DRUG

SHR-1209 ;placebo

SHR-1209 and placebo 450 mg subcutaneous injection once every 12 weeks for 48 weeks

Trial Locations (1)

100029

Beijing Anzhen hospital, Beijing

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT04885218 - Efficacy and Safety of SHR-1209 Combined With Lipid-lowering Agents in Patients With Hypercholesterolemia | Biotech Hunter | Biotech Hunter